Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Current and Projected Market Size of the Preventive Vaccines Industry?

The market size for preventive vaccines has seen significant expansion in the past years. The market is projected to escalate from $75.94 billion in 2024 to a whopping $81.39 billion in 2025, yielding a compound annual growth rate (CAGR) of 7.2%. Factors contributing to this historic growth include heightened government support, increased consciousness about infectious diseases, an upsurge in worldwide immunization initiatives, advancements in vaccine technology, and a surge in the requirement for childhood vaccination.

The market for preventive vaccines is predicted to witness considerable expansion in the upcoming years, with an expected value of $106.47 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.9%. This growth within the prediction span can be linked to the escalated investment in vaccine research, the increasing occurrence of infectious diseases, the soaring demand for tailor-made vaccines, amplified government initiatives and backing, along with the increasing incorporation of advanced vaccine technologies. The forecast period witnesses various key trends, inclusive of the progression in mRNA vaccine technology, the development of advanced delivery systems, the emergence of innovative nanoparticle-based vaccines, engagement of artificial intelligence in vaccine research, and the rise in cold chain logistics.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24667&type=smp

#Which Factors Are Currently Driving The Growth Of The Preventive Vaccines Market?

The surge in infectious diseases is predicted to drive the expansion of the preventive vaccines market. These diseases are illnesses caused by microorganisms like bacteria, viruses, fungi or parasites, which are easily transmitable from one person to another or through environmental mediums. The increase in infectious diseases is primarily due to factors such as growing urbanization, international travel, and antimicrobial resistance. These factors contribute to the quick spread and difficulties in containment of these infections. Vaccines for prevention aid in controlling these diseases as they stimulate the immune system to identify and counteract pathogens before they get a chance to infect, this decreases disease occurrence and transmission. For example, in July 2024, the Australian Institute of Health and Welfare, a government agency in Australia, declared that in 2022, infectious diseases resulted in over 15,770 fatalities in Australia. Of these, a third were due to lower respiratory infections which are non-notifiable disease deaths. This rise in the prevalence of infectious diseases drives the expansion of the preventive vaccines market.

How Is The Global Preventive Vaccines Market Structured In Terms Of Segments?

The preventive vaccines market covered in this report is segmented –

1) By Type: Live Or Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit Vaccines, Conjugate Vaccines, DNA Vaccines, Recombinant Vector Vaccines

2) By Disease Type: Pneumococcal, Poliovirus, Hepatitis, Influenza, Measles, Rubella, Other Disease Types

3) By Age Group: Pediatric, Adult, Geriatric

4) By Distribution Channel: Hospitals, Clinics, Pharmacies, Other Distribution Channels

Subsegments:

1) By Live or Attenuated Vaccines: Measles, Mumps, and Rubella (MMR) Vaccine, Varicella (Chickenpox) Vaccine, Oral Polio Vaccine (OPV), Yellow Fever Vaccine, Rotavirus Vaccine, Bacillus Calmette-Guérin (BCG) Vaccine

2) By Inactivated Vaccines: Inactivated Poliovirus Vaccine (IPV), Hepatitis A Vaccine, Rabies Vaccine, Influenza (Inactivated) Vaccine, Japanese Encephalitis Vaccine

3) By Toxoid Vaccines: Tetanus Toxoid Vaccine, Diphtheria Toxoid Vaccine, Pertussis (whooping cough) Vaccine

4) By Subunit Vaccines: Hepatitis B Vaccine, Human Papillomavirus (HPV) Vaccine, Pertussis (acellular) Vaccine, Influenza (recombinant protein) Vaccine

5) By Conjugate Vaccines: Pneumococcal Conjugate Vaccine (PCV), Haemophilus influenzae type b (Hib) Vaccine, Meningococcal Conjugate Vaccine

6) By DNA Vaccines: Zika Virus DNA Vaccine, Cytomegalovirus (CMV) DNA Vaccine, Infectious Disease DNA Vaccines

7) By Recombinant Vector Vaccines: Ebola Vaccine (rVSV-ZEBOV), COVID-19 Recombinant Vector Vaccines, Dengue Recombinant Vector Vaccines

What Trends Are Currently Influencing Growth In The Preventive Vaccines Market?

Major preventive vaccines market players are prioritizing advancements in vaccine technology, including advanced mRNA technology platforms. These innovations aim to improve the efficacy and safety of vaccines, expedite their production and development, and offer a more comprehensive defense against emerging infectious disease variants. Advanced mRNA technology platforms use messenger RNA to guide cells to create specific proteins, thus stimulating a targeted immune reaction. In March 2025, a notable example occurred when Moderna Inc., a biotech firm based in the United States, received FDA approval for their new COVID-19 vaccine mNEXSPIKE (mRNA-1283), designed for adults 65 years or older and 12 to 64 years old individuals who have one or more risk factors identified by the CDC. The release of mNEXSPIKE represents a huge step forward in the next wave of mRNA vaccine technology, as it offers superior stability and storage ease compared to previous models. This move is set to raise vaccine accessibility and distribution, especially in remote and underprivileged areas.

Who Are The Main Participants Shaping The Preventive Vaccines Market Landscape?

Major companies operating in the preventive vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Sanofi Pasteur SA, AstraZeneca plc, GlaxoSmithKline plc (GSK), Takeda Pharmaceutical Company Limited, Moderna Inc., CSL Limited, Novavax Inc., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Serum Institute of India Pvt. Ltd., Vaxcyte Inc., Bavarian Nordic A/S, Valneva SE, Panacea Biotec Ltd., Inovio Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, Afrigen Biologics and Vaccines (Pty) Ltd.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report

Which Region Currently Holds The Largest Share In The Preventive Vaccines Market?

North America was the largest region in the preventive vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preventive vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24667&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model